CompletedNot Applicable

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

United States21 participantsStarted 2013-12

Plain-language summary

This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons. Exercise therapy may help improve quality of life, may increase exercise capacity, and may reduce inflammation and oxidative stress in patients with lung cancer and their supporters.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * LUNG CANCER PATIENTS: A confirmed diagnosis of any stage lung cancer (non-small cell lung cancer \[NSCLC\] or small cell lung cancer \[SCLC\]) * LUNG CANCER PATIENTS: Can be receiving any type of treatment (chemotherapy, radiation therapy, both or neither) are eligible * LUNG CANCER PATIENTS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires * LUNG CANCER PATIENTS: For patients treated with curative intent, and who have not relapsed, they must be within 1 year of their diagnosis of lung cancer (determined by date of diagnostic pathology sample) * SUPPORT PERSONS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires Exclusion Criteria: * LUNG CANCER PATIENTS: Symptomatic heart disease including congestive heart failure or arrhythmia * LUNG CANCER PATIENTS: Documented myocardial infarction in the last three months * LUNG CANCER PATIENTS: Central nervous system (CNS) metastases that results in impaired ability to participate in an exercise program at the discretion of the study physician * LUNG CANCER PATIENTS: Any psychological or physical disease that would impair or prevent participation in an exercise program at the discretion of the study physician * LUNG CANCER PATIENTS: Cognitive or reading impairments that would preclude them from completing questionnaires * LUNG CANCE…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in biomarkers of inflammation

Timeframe: Baseline up to 8 weeks

Change in oxidative damage as indicated by serum 8-hydroxydeoxyguanosine (8-oh-dG)

Timeframe: Baseline up to 8 weeks

Change in time to walk 400 m

Timeframe: Baseline up to 8 weeks

Change in physical well-being scores on the Functional Assessment of Cancer Therapy-Lung (FACT-L)

Timeframe: Baseline up to 8 weeks

Change in functional well-being scores on the FACT-L

Timeframe: Baseline up to 8 weeks

Trial details

NCT IDNCT01999881

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-07

View on ClinicalTrials.gov More Extensive Stage Small Cell Lung Cancer trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in biomarkers of inflammation

Timeframe: Baseline up to 8 weeks

Change in oxidative damage as indicated by serum 8-hydroxydeoxyguanosine (8-oh-dG)

Timeframe: Baseline up to 8 weeks

Change in time to walk 400 m

Timeframe: Baseline up to 8 weeks

Change in physical well-being scores on the Functional Assessment of Cancer Therapy-Lung (FACT-L)

Timeframe: Baseline up to 8 weeks

Change in functional well-being scores on the FACT-L

Timeframe: Baseline up to 8 weeks